Back to Search
Start Over
Detrimental effects of performance-enhancing drugs on the heart: a case report of anabolic steroid induced cardiomyopathy.
- Source :
-
Cardiologia Croatica . Nov/Dec2023, Vol. 18 Issue 11/12, p308-309. 2p. - Publication Year :
- 2023
-
Abstract
- Introduction: Synthetic anabolic androgenic steroids (AAS), compounds mimicking the action of endogenous testosterone in enhancing training performance, have been extensively studied during the last century. AAS abuse has become a major public health concern with an estimated worldwide lifetime prevalence of 1–5%1 . Long-term administration of AAS in supraphysiological doses may have detrimental effects on the cardiovascular system, presumably through direct action on cardiac myocyte androgen receptors. In severe cases, life-threatening conditions such as myocardial infarction, aortic dissection or cardiomyopathy, particularly dilated cardiomyopathy as the most common form, may occur. Hereby, we report a rare case of AAS-induced cardiomyopathy with an emphasis on the multidisciplinary approach. Case report: 46-year-old male bodybuilder presented with exercise intolerance unrelated to maximum training load and post-workout water retention 6 weeks before the visit. History revealed previous administration of testosterone enanthate 500 mg every 8 to 12 days during the period of 4 years. After a month-long cessation, he started taking testosterone undecanoate 1000 mg in 6-week intervals. The cardiorespiratory part of the physical examination showed normal findings and blood pressure of 125/80 mmHg. The patient was of athletic build with no signs of increased hairiness and no palpable testicular mass. An electrocardiogram showed a normal electrical axis and sinus bradycardia. Laboratory assessment (Table 1) was followed by echocardiography which was in accordance with the diagnosis of AAS-induced cardiomyopathy (Figure 1). Further diagnostic assessment of osteoporosis, hepatic, renal and psychological complications was performed. Conclusion: Long-term administration of AAS with unknown pharmacokinetic and pharmacodynamic properties should be considered as a cause of newly diagnosed cardiomyopathy, especially in previously healthy individuals with an athletic background. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1848543X
- Volume :
- 18
- Issue :
- 11/12
- Database :
- Academic Search Index
- Journal :
- Cardiologia Croatica
- Publication Type :
- Academic Journal
- Accession number :
- 173376123
- Full Text :
- https://doi.org/10.15836/ccar2023.308